Pfizer in Puurs develops potential vaccine for Bronchiolitis.

The American firm hopes to obtain marketing authorization for its candidate vaccine against RSV, the virus that causes bronchiolitis, by the fall. In Puurs, investments are planned so that the Belgian production plant can continue to keep pace.

Article reserved for subscribers

Journalist at the service of society

Reading time: 4 mins

After having achieved 100 billion dollars in turnover in 2022 (57% of which thanks to its vaccines against covid), the American Big Pharma is reinvesting its dividends. It has just bought out the American biotech Seagen, which specializes in the research and development of cancer treatments for an amount of 43 billion dollars (40.1 billion euros). At the end of December, the American firm also announced an investment of 1.2 billion over three years for its Belgian site in Puurs, which employs 4,500 people.

This article is for subscribers only

With this offer, enjoy:
  • Unlimited access to all the articles, files and reports of the editorial staff
  • The newspaper in digital version
  • Reading comfort with limited advertising

Read more:  COVID-19 | Vaccination | The commitment is for a safe return to the classroom: how to prepare for the return to face-to-face school classes | LIME

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick